Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ARAY · against 19 other Healthcare companies of similar size
Ranked #9 of 20 · scores higher than 26% of peers
Bars: peers in each 10-point band of the valuation score12 peers with a valuation score of 0–9, including ARAY · Click a bar to see the companies
Mainly because of its earnings yield, free cash flow yield and EBITDA yield, which are weaker than most Healthcare peers.
| Metric | ARAY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 19 reported | -285.7% | -118.3% | 11% | 30% | |
| EBITDA yieldHigher is better · 23 reported | -2.2% | -15.6% | 64% | 50% | |
| Free cash flow yieldHigher is better · 13 reported | -115.2% | -115.2% | 50% | 20% | |
| Book yieldHigher is better · 22 reported | 249.3% | 96.8% | 86% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 14.3B KRW (≈$10M) | 71 | 53 | |
| 2 | 3.5B JPY (≈$24M) | 65 | 48 | |
| 3 | 30M USD | 33 | ||
| 3 | 23M USD | 33 | ||
| 3 | 22M USD | 33 | 47 | |
| 3 | 17M USD | 33 | 10 | |
| 7 | 21.3B KRW (≈$15M) | 30 | 28 | |
| 7 | 12M USD | 30 | 38 | |
| 9 | 17M USD | 8 | 16 | |
| 9 | 250M SEK (≈$25M) | 8 | 44 | |
| 9 | 17M USD | 8 | 18 | |
| 9 | 390.5B IDR (≈$24M) | 8 | 8 | |
| 9 | 298M SEK (≈$30M) | 8 | 48 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score